9/8/2009

Spectrum Pharmaceuticals secured FDA approval to promote Zevalin as a first-line treatment for non-Hodgkin's lymphoma. The approval was based on late-stage trial results proving the drug's efficacy as first-line therapy on 414 patients.

Related Summaries